Showing 251-260 of 1100 results for "".
Viewpoint: What Does Private Equity in Dermatology Mean for Residents and Millennial Dermatologists?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/viewpoint-what-does-private-equity-in-dermatology-mean-for-residents-and-millennial-dermatologists/23107/One resident’s take on the pros and cons of PE-backed employment and other opportunities for new dermatologists.A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis
https://practicaldermatology.com/topics/psoriasis/a-practical-approach-to-home-uvb-phototherapy-for-the-treatment-of-generalized-psoriasis/21926/Specialists review the basics of choosing ideal patients for home UVB, delineate key aspects of patient education, and provide detailed information on currently available phototherapy equipment.Insights on Care for Skin of Color, Part 2
https://practicaldermatology.com/topics/skin-of-color/insights-on-care-for-skin-of-color-part-2/18185/Hilary Baldwin, MD and James Q. Del Rosso, DO continue their discussion with host Neal Bhatia, MD about managing skin of color. They address long-term management strategies and the need for cultural awareness.Fillers for the Décolletage Area
https://practicaldermatology.com/topics/practice-management/fillers-for-the-dcolletage-area/21113/Fillers offer patients an alternative to device-based interventions for chest rejuvenation.o, MDPanel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launcDiverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyLasers and EBDs: Considerations for Ethnic Skin
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/lasers-and-ebds-considerations-for-ethnic-skin/20145/Monica Li, MD reviews evidence-based practices for using lasers, energy-based devices and minimally invasive procedures to manage benign dermatoses to treat patients with skin of color. She discusses the importance of engaging patients in appropriate pre- and post-treatment care to reduce potentialCOVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-A Matter of Scales
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/a-matter-of-scales/19917/The "classic" descriptions of skin diseases and the scales used to assess disease severity often are based on white skin. But skin diseases can appear differently across skin types. The panelists discuss the need for updated tools, including the need to rethink skin type scales.Up the Authenticity Factor on Your Dermatology Social Media
https://practicaldermatology.com/topics/practice-management/up-the-authenticity-factor-on-your-dermatology-social-media/23423/Strike the right tone and find the balance needed to truly engage with your current and potential patients.